PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. METHODS Sera…
Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of…
Background Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a…
This review describes the registry efforts made during the COVID-19 pandemic with the aim of investigating and sharing information about the history, risk factors, and…
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
AbstractBackground. The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronaviru
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of…
Click on the article title to read more.
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with…
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and…
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not…
